Syndax Pharmaceuticals (SNDX) Non-Current Assets (2015 - 2026)

Syndax Pharmaceuticals' Non-Current Assets history runs 12 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 98.38% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $89.6 million (down 64.97% YoY), while the FY2025 annual figure was $1.6 million, down 98.67% from the prior year.
• Non-Current Assets was $1.5 million for Q1 2026 at Syndax Pharmaceuticals, down from $1.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $121.8 million in Q4 2024 to a low of $1.5 million in Q1 2026.
• Historically, Non-Current Assets has averaged $32.4 million across 5 years, with a median of $18.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 2707.54% in 2022, then plunged 98.67% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $7.4 million in 2022, then surged by 329.58% to $32.0 million in 2023, then jumped by 280.45% to $121.8 million in 2024, then slumped by 98.67% to $1.6 million in 2025, then fell by 8.25% to $1.5 million in 2026.
• The last three Non-Current Assets figures came in at $1.5 million (Q1 2026), $1.6 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.